< Back to Article

A Phase 1 Study of ¹³¹I-CLR1404 in Patients with Relapsed or Refractory Advanced Solid Tumors: Dosimetry, Biodistribution, Pharmacokinetics, and Safety

Figure 1

Consort diagram and clinical outcome of enrolled patients.

Patients were taken off of conventional therapies from two weeks prior to and 30 days after treatment with ¹³¹I-CLR1404. After treatment with ¹³¹I-CLR1404, patients underwent nuclear medicine procedures for 14 days and were followed for safety for 42 days.

doi: https://doi.org/10.1371/journal.pone.0111652.g001